Review Article

Not All Probiotics Are Equal: Strain-Specific Effects on IBS Symptoms

[1]Jay Rajiv Shinde*, [2]Srushti Moreshwer Patil, [3]Saloni Gajakos, [4]Dhwani Jignesh Shah, [5]Laiba Khan
[1]Medical Officer, MGM Medical College & Hospital, Navi Mumbai, Maharashtra, India.
[2] Intern, SMBT Medical College, Nasik, Maharashtra, India.
[3]Intern, GGMC & JJH, Mumbai, Maharashtra, India.
[4]Medical Graduate, GGMC & JJH, Mumbai, Maharashtra, India.
[5]Medical Officer, MGM Medical College & Hospital, Navi Mumbai, Maharashtra, India.
***Corresponding author's E-mail:** Jays71@protonmail.com

Received: 06-03-2025; **Revised:** 28-05-2025; **Accepted:** 05-06-2025; **Published online:** 15-06-2025.

ABSTRACT

Background: Probiotics have been suggested as a treatment for Irritable Bowel Syndrome (IBS), a common functional gastrointestinal illness marked by bloating, changed bowel habits, and persistent stomach pain; however, their effectiveness seems to be strain specific.

Objective: The purpose of this study is to figure out gaps in research and to assess the therapeutic effects of specific probiotic strains on adult IBS symptoms, with an emphasis on bloating, irregular bowel movements, and abdominal discomfort.

Methods: Up until April 2025, a thorough literature search was carried out in the Cochrane Library, PubMed, and Embase. Research that involved individuals with IBS utilizing Rome criteria, specific probiotic strains, and reported results on bloating, diarrhea, or stomach discomfort were included if it was a randomized controlled trial or cohort study.

Results: Research suggests that several single-strain probiotics, like Bacillus coagulans IS-2 and Lactobacillus plantarum 299v, considerably reduce the symptoms of IBS. Others, however, such as single-strain Bifidobacterium infantis 35624 and Lactobacillus casei Shirota, exhibit only modest effectiveness. Variable results are obtained with multi-strain formulations. Mechanistically, some strains improve the integrity of the gut barrier, which lowers intestinal permeability, while others modify cytokines such as IL-10 and TNF-α, which affect pain and motility.

Conclusion: The effectiveness of probiotics in IBS varies with strain. To better understand and use probiotics in the management of IBS, future research should concentrate on strain-specific benefits, standardized procedures, and long-term outcomes.

Keywords: IBS: Irritable Bowel Syndrome, IBS-C: Constipation-predominant Irritable Bowel Syndrome, IBS-D: Diarrhea-predominant Irritable Bowel Syndrome, IBS-M: Mixed-type Irritable Bowel Syndrome, RCT: Randomized Controlled Trial, CFU: Colony Forming Units, SCFA: Short-Chain Fatty Acids, TNF-α: Tumor Necrosis Factor Alpha, QOL: Quality of Life, SMD: Standardized Mean Difference, CI: Confidence Interval.

INTRODUCTION

A large percentage of adults globally suffer from Irritable Bowel Syndrome (IBS), which causes significant morbidity and healthcare utilization[1]. Constipation-predominant (IBS-C), diarrhea-predominant (IBS-D), and mixed-type (IBS-M)[1] are among the subtypes of the illness, which is typified by persistent stomach pain, bloating, and changed bowel habits. IBS has a complex etiology that includes immunological activation[2], visceral hypersensitivity, altered gastrointestinal motility, and disruption of the gut-brain axis.

Probiotics, which are live microorganisms that provide health advantages when taken in sufficient quantities, have been investigated as a potential treatment for IBS[3]. Probiotic effectiveness, however, seems to vary by strain, with some strains exhibiting substantial symptom relief and others exhibiting little to no benefit[4]. Optimizing the use of probiotics in the treatment of IBS requires an understanding of the strain-specific effects of these supplements.

Methodology

For papers published up until April 2025, a thorough literature search was carried out in the databases of the Cochrane Library, PubMed, and Embase. "Irritable Bowel Syndrome," "IBS," "probiotics," "strain-specific," and the names of certain probiotic strains were among the search terms used.

Inclusion Criteria:

- Either cohort studies or Randomized controlled trials

- Studies involving adults (≥18 years) diagnosed with IBS based on Rome III or IV criteria

- Studies specifying the probiotic strain(s) used

- Studies reporting outcomes on abdominal pain, bloating, or stool patterns

Exclusion Criteria:

- Studies involving pediatric populations

- Studies without clear specification of probiotic strains

- Studies lacking quantitative outcome measures

- Non-English language publications

Data extracted included study design, sample size, IBS subtype, probiotic strain(s), dosage, duration of intervention, and reported outcomes on IBS symptoms.

Results

Lactobacillus plantarum 299v: A four-week course of L. plantarum 299v therapy dramatically decreased the frequency and intensity of stomach pain in IBS patients, as well as bloating, according to a multicenter randomized controlled experiment.[7] These results were not replicated in an eight-week trial, though, indicating that efficacy varies depending on the population or research design.[8]

Bacillus coagulans IS-2: Over the course of eight weeks, B. coagulans IS-2 dramatically reduced IBS patients' bloating, frequency of bowel movements, abdominal pain, and satisfaction in a randomized controlled experiment.[9]

Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07: A double-blind trial discovered that this two-strain combination effectively reduced bloating in patients with functional bowel disorders, including IBS.[10]

Bifidobacterium infantis 35624: A meta-analysis suggested that composite probiotics containing B. infantis 35624 might reduce IBS symptoms, although the efficiency of the single strain is yet unknown.[11]

Lactobacillus casei Shirota: L. casei Shirota did not significantly reduce IBS symptoms in an eight-week randomized controlled experiment when compared to a placebo.[12]

Saccharomyces boulardii: There is little evidence to support this probiotic made of yeast. Although some research points to possible advantages, the findings are erratic and lack strong control groups.[13]

Multi-strain formulations: Variable results have been observed with products such as VSL#3. While some studies find no discernible benefit, others indicate improved intestinal transit and decreased flatulence.[14]

Table 1: Summary of Clinical Trials by Probiotic Strain[1–12]

Probiotic Strain (Dose, Duration)	Population & Design	Symptom Outcomes
Lactobacillus plantarum 299v (DSM 9843, 10^9 CFU, 4 weeks)	IBS (Rome III, n=214), RCT, placebo-controlled	Pain↓, Bloating↓, Global symptom relief↑
Bacillus coagulans IS-2 (MTCC 5260, 60×10^9 CFU, 8 weeks)	IBS (n=108), RCT, placebo-controlled	Pain↓, Bloating↓, Stool satisfaction↑
L. acidophilus NCFM + *B. lactis* Bi-07 (2×10^11 CFU/day, 8 weeks)	FBD/IBS (n=60), RCT, double-blind	Bloating↓
Bifidobacterium infantis 35624 (varied doses, multiple studies)	IBS (n varies), Meta-analysis	Pain↓ (in combinations), Bloating↓ (modest effect)
Lactobacillus casei Shirota (Yakult, 8 weeks)	IBS-C (n=80), RCT, double-blind	No significant improvement
Saccharomyces boulardii (500 mg/day, 1 month)	IBS-D and IBS-M (n≈60), RCT, small sample	Limited evidence, inconsistent results
VSL#3 (multi-strain, 900×10^9 CFU, 4–8 weeks)	IBS (Rome II/III, n=243), Meta-analysis of 5 RCTs	Variable; trend towards improvement in global response
Lactobacillus paracasei CNCM I-1572 (pilot trial, 4 weeks)	IBS (n=60), RCT, pilot study	Reduced pain, improved microbiota & SCFAs
Bifidobacterium bifidum MIMBb75 (varied doses, 4 weeks)	IBS (n=122), Double-blind RCT	Improved pain, QOL↑
Bio-Kult® (multi-strain, 4 weeks)	IBS-D (n=82), RCT, placebo-controlled	Pain↓, Frequency↓, Overall symptoms improved



Figure 1: Symptom Relief by Probiotic Strain[1–12]

The strength of evidence for ten probiotic therapies used in IBS research is compared in Figure 1 for pain, bloating, and stool improvement. Synthesized clinical outcomes are reflected in each score (0 = no effect, 1 = strong effect, and 0.5 = moderate or mixed results).

DISCUSSION

Probiotic efficacy in IBS is evidently strain dependent. Strains that outperform placebo for pain and relief from bloating are L. plantarum 299v and B. coagulans IS-2 [7,9] whereas strains such as L. casei Shirota and single-strain B. infantis 35624 do not do so[12,11].

By reducing pro-inflammatory TNF-α and raising anti-inflammatory cytokines like IL-10, some probiotics mechanistically alter mucosal immunity, which is associated with reductions in stomach pain and motility.[15,16]. Table 2 summarizes these physiological and immunological consequences, which vary by strain: The Ways in Which Certain Probiotic Strains Work[10,11,15-17,20].

Table 2: Mechanisms of Action of Selected Probiotic Strains[10,11,15-17,20]

Probiotic Strain	Mechanism of Action
L. plantarum 299v	Enhances tight junctions, reduces gut permeability, anti-inflammatory cytokine modulation
B. coagulans IS-2	Immune modulation, TNF-α suppression, IL-10 upregulation
L. acidophilus NCFM + *B. lactis* Bi-07	Reduces gas and bloating via fermentation balance and immune signaling
B. infantis 35624	Increases IL-10, decreases TNF-α, alters gut flora
L. paracasei CNCM I-1572	Improves mucosal barrier, modulates SCFA production and inflammation
B. bifidum MIMBb75	Adheres to intestinal cells, reduces pain sensitivity, enhances barrier function
B. longum BB536	Enhances immune function, modulates microbiota in elderly patients

Furthermore, by upregulating tight junction proteins, certain strains strengthen the integrity of the intestinal barrier and lower gut permeability, a crucial component of the pathogenesis of IBS.[17]. For example, L. plantarum 299v positively modifies tight junction function and decreases gut inflammation[7,15] while B. coagulans IS-2 changes the immune system and promotes anti-inflammatory signaling via IL-10 upregulation[9,16]. Other types of strains like L. paracasei CNCM I-1572 and B. bifidum MIMBb75 enhance mucosal repair and affect pain and quality of life via immunity and barrier mechanisms[10,15,17].

The difference in efficacy between strains is all the more illustrated in Figure 1: Symptom Relief by Probiotic Strain[1–14], which compares the strengths of evidence for symptom improvement amongst ten common probiotics in IBS trials.

Even though these promising findings exist, the current literature has quite a few limitations which include heterogeneity in study designs, inadequately small sample sizes, short intervention durations, and not enough long-term follow-up. Also, many studies do not segregate outcomes based on IBS subtypes (IBS-C, IBS-D, IBS-M), which may influence response to specific strains.

CONCLUSION

The effectiveness of probiotic therapy for IBS depends on the choice of evidence-based strains; it cannot be regarded as a standard intervention. When making probiotic recommendations, clinicians must consult strain-specific data. Effective integration of probiotics into the care of IBS will require well-designed, subtype-stratified trials with mechanistic objectives.

Source of Support: The author(s) received no financial support for the research, authorship, and/or publication of this article

Conflict of Interest: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

REFERENCES

1. Hong KS, Kang HW, Im JP, Ji GE, Kim SG. Effect of probiotics on symptoms in Korean adults with irritable bowel syndrome. Gut Liver. 2009;3(2):101–7.
2. Camilleri M. Review article: current and novel treatments for IBS. Aliment Pharmacol Ther. 2018;47(2):49–62.
3. Moreno MA, Liu LY, Vandenplas Y. Probiotic use in childhood diarrhoea and constipation. J Pediatr Gastroenterol Nutr. 2019;68(Suppl 2):S42–8.
4. Ford AC, Harris LA, Lacy BE, Quigley EMM, Moayyedi P. Systematic review with meta-analysis: the efficacy of probiotics in IBS. Aliment Pharmacol Ther. 2018;48(10):1044–57.
5. Whorwell PJ, Altringer L, Morel J, Bond Y, Charbonneau D, O'Mahony L, et al. Efficacy of Bifidobacterium infantis 35624 in women with IBS. Am J Gastroenterol. 2006;101(7):1581–90.
6. Ishaque SM, Khosruzzaman SM, Ahmed DS, Sah MP. A randomized placebo-controlled clinical trial of a multi-strain probiotic formulation (Bio-Kult®) in the management of diarrhea-predominant irritable bowel syndrome. BMC Gastroenterol. 2018;18(1):71.
7. Ducrotté P, Sawant P, Jayanthi V. Clinical trial: Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome. World J Gastroenterol. 2012;18(30):4012–8.

8. Stevenson C, Blaauw R, Fredericks E, Visser J, Roux S. Randomized clinical trial: effect of Lactobacillus plantarum 299v on symptoms of irritable bowel syndrome. Nutrition. 2014;30(10):1151–7.
9. Madempudi RS, Ahire JJ, Neelamraju J, Tripathi A, Nanal S. Randomized clinical trial: the effect of probiotic Bacillus coagulans Unique IS2 vs. placebo on the symptoms management of irritable bowel syndrome in adults. Sci Rep. 2019;9(1):12210.
10. Ringel Y, Ringel-Kulka T, Maier D, Carroll I, Galanko J, Leyer G. Probiotic bacteria Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07 versus placebo for the symptoms of bloating in patients with functional bowel disorders: a double-blind study. J Clin Gastroenterol. 2011;45(6):518–25.
11. Zhang Y, Li L, Guo C, Mu D, Feng B, Zuo X, et al. Efficacy of Bifidobacterium infantis 35624 in patients with irritable bowel syndrome: a meta-analysis. Curr Med Res Opin. 2017;33(7):1191–7.
12. Koebnick C, Wagner I, Leitzmann P, Stern U, Zunft HJ. Probiotic beverage containing Lactobacillus casei Shirota improves gastrointestinal symptoms in patients with chronic constipation. Can J Gastroenterol. 2003;17(11):655–9.
13. Guslandi M. Treatment of irritable bowel syndrome with Saccharomyces boulardii. J Clin Gastroenterol. 2011;45(8):740–1.
14. Kim HJ, Vazquez Roque MI, Camilleri M, Stephens D, Burton DD, Baxter K, et al. A randomized controlled trial of a probiotic combination VSL#3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil. 2005;17(5):687–96.
15. Guglielmetti S, Mora D, Gschwender M, Popp K. Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life—a double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2011;33(10):1123–32.
16. Ceccherini C, Daniotti S, Bearzi C, Re I. Evaluating the efficacy of probiotics in IBS treatment using a systematic review of clinical trials and multi-criteria decision analysis. Nutrients. 2022;14(13):2689.
17. Cremon C, Guglielmetti S, Gargari G, Taverniti V, Castellazzi AM, Valsecchi C, et al. Effect of Lactobacillus paracasei CNCM I-1572 on symptoms, gut microbiota, short chain fatty acids, and immune activation in patients with irritable bowel syndrome: a pilot randomized clinical trial. United European Gastroenterol J. 2018;6(4):604–13.
18. Guglielmetti S, Tamagnini I, Minuzzo M, Mora D, Parini C, Baldassarre ME, et al. Implication of an outer surface lipoprotein in adhesion of Bifidobacterium bifidum to Caco-2 cells. Appl Environ Microbiol. 2008;74(15):4695–702.
19. Turroni F, Serafini F, Foroni E, Duranti S, O'Toole PW, Motherway MO, et al. Role of sortase-dependent pili of Bifidobacterium bifidum PRL2010 in modulating bacterium–host interactions. Proc Natl Acad Sci U S A. 2013;110(27):11151–6.
20. Hojo M, Nagaoka K, Ohshima T, Murakami K, Nishikawa Y, Onaka A, et al. Effect of Bifidobacterium longum BB536 on immune function and intestinal microbiota in elderly patients receiving enteral nutrition. J Parenter Enteral Nutr. 2013;37(5):631–40.